AbbVie HCV drugs show high cure rate in another late-stage study
This article was originally published in Scrip
Executive Summary
AbbVie’s hepatitis C drug regimen showed a 96% cure rate in a late-stage trial of chronically infected patients. The top line results are from the second of six studies by the company conducted to win US and European approval.